Introduction
Growth factors and their receptors play an essential role in the regulation of epithelial cell proliferation. It has been demonstrated that abnormalities in growth factor expression and action contribute to the progression and maintenance of the malignant phenotype. For example, overexpression of HER2 is frequently associated with an aggressive clinical course and increased metastasis in human breast cancer (Slamon et al., 1987) . Recently, additional members, HER3 and HER4, have been added to the HER2 family, as these receptors share sequence homology with the tyrosine kinase domain of HER (Reese and Slamon, 1997) . This family of receptors can be transactivated by receptor-receptor interaction in a ligand-dependent manner and thus can use more than one pathway to execute their biological functions (Carraway and Cantley, 1994; Hynes and Stern, 1994; Reese and Slamon, 1997) .
Mammary gland development proceeds in distinct stages de®ned by the hormonal status of the animal (Hennighausen and Robinson, 1998) . However, HRG, a combinatorial ligand for HER3 and HER4, is a secretory polypeptide that aects growth stimulation, dierentiation, invasiveness, and migration of breast cancer cells (Peles et al., 1992; Burden and Yarden, 1997; Adam et al., 1998; Yang et al., 1995; Marte et al., 1995; Jones et al., 1996) . In mammary epithelial cells, HRG predominantly use HER3/HER2 to exact its biological eects (Hynes and Stern, 1994) . Additionally, HRG is known to be expressed in the mammary mesenchyma adjacent to lobuloalveolar structures and is maximally expressed during pregnancy (Jones et al., 1996) . HRG also plays a role in the morphogenesis and ductal migration of mammary epithelial cells (Jones et al., 1996; Yang et al., 1995) and promotes the in vitro responsiveness of these cells to lactogenic hormones (Marte et al., 1995) . Finally, ectopic delivery of HRG to the mammary fat pad via implanted pellets induces the dierentiation of mammary epithelium into secretory lobuloalveoli (Jones et al., 1996) . Although these observations suggest that HRG plays an important role in the biology of mammary epithelial cells, the mechanism by which HRG aects the diverse phenotypic alterations in mammary epithelial cells remains poorly understood.
It is widely believed that induction of a set of early growth-responsive (also known as immediate early) genes, in the absence of de novo protein synthesis may constitute the ®rst step in the cellular molecular response to extracellular signals. Transcription of protein-coding genes is one of the major regulatory steps in gene expression. One of the major regulatory elements that contribute to transcriptional regulation of extracellular signals is the cAMP responsive element (CRE). The process of transcription involves physical interactions between sequence-speci®c DNA-binding transcriptional activations and the general transcription factor directly, indirectly, or both (Goodrich et al., 1996) . It is increasingly being accepted that the CRE site is recognized by a family of bZIP containing proteins known as CRE-binding proteins (CREB). bZIP containing proteins need to dimerize for productive DNA binding (Janknecht and Hunter, 1996) . The dimeric bZIP proteins are characterized by a bipartite alpha-helical structure in which the basic amino-terminal half of the motif interacts with sequence-speci®c DNA, whereas the carboxyl-terminal half of the motif dimerizes to form a leucine zipper (Janknecht and Hunter, 1996; Vinson et al., 1993) . These bZIP containing factors not only homodimerize but also heterodimerize. In addition, the members of CCAAT/enhancer binding protein (C/EBP) family of transcription factors, including growth arrest and DNA damage-inducible protein 153 (GADD153) dimerize with speci®c bZIP proteins at the leucine zipper (Vinson et al., 1993) . Because binding sites for ATFs are present in several growth-regulating cellular promoters (Verrijzer and Tjian, 1996) , they are believed to be involved in dierent regulatory circuits, allowing cells to integrate signals from distinct pathways.
Several proliferation-modulating genes contain a CCAAT-enhancer site for the bZIP-factors. These genes have been shown to regulate diverse cellular functions, such as stress, dierentiation, cell typespeci®c genes, and growth arrest, by modulating the transcription of target genes (Batchvarona et al., 1995; Cao et al., 1991; Ron and Habener, 1992; Fornace et al., 1989) . GADD153, like other bZIP factors, can heterodimerize with other bZIP factors, including C/ EBP family members and ATF3 (Ron and Habener, 1992; Wolfgang et al., 1997) . However, due to substitutions of several amino acids in the bZIP domain (Ron and Habener, 1992) , GADD153 heterodimers with C/EBP or ATF3 are unable to bind to the DNA. Hence, GADD153 has been implicated as a negative regulator of C/EBP-or ATF3-mediated gene activation and functions (Fawcett et al., 1996; Chen et al., 1996) . However, under certain conditions, GADD153/C/EBP heterodimers may also activate transcriptional activity via interactions with novel DNA-binding motifs (Ubeda et al., 1996; Fawcett et al., 1999) . The expression of GADD153 has been shown to be induced in response to nutrient deprivation (Huang et al., 1999) and genotoxic agents and stress in the endoplasmic reticulum (Zinszer et al., 1998) and by growth arrest (Zhan et al., 1994) . Also, overexpression of GADD153 in murine 3T3 cells has led to growth arrest at the G1/S phase of the cell cycle (Barone et al., 1994) , and cell death in human cells (Matsumoto et al., 1996) . Furthermore, the expression of GADD153 was shown to be upregulated during dierentiation, which could also be accelerated by ectopic overexpression of GADD153 (Coutts et al., 1999) . The signi®cance of GADD153 in human cancer cells was further evidenced by the following recent ®nding; the occurrence of a novel breakpoint fusion protein consisting of GADD153 and a new RNAbinding protein in soft-tissue sarcomas (Crozat et al., 1993) , the upregulation of GADD153 in human cells expressing BRCA1 (MacLachlan et al., 2000) , and the ability of GADD153 to interact with a v-fos transformation eector (FTE) in a two-hybrid screen (Cui et al., 2000) . Together, current evidence suggests that GADD153 expression may not be limited to genotoxic responses and that GADD153 may in¯uence cellular functions in both a C/EBP-dependent andindependent manner. Very little is known, however, about HRG regulation of GADD153 and whether it has any role in mammary epithelial cells.
To understand the cellular basis of the diverse functions of HRG, we conducted Atlas cDNA Gene Array screening using RNA isolated from human cells treated with or without the anti-HER2 antibody Herceptin (transruzumab) and identi®ed GADD153 as a growth factor-inducible gene in mammary epithelial cells. We show that recombinant HRG upregulates the expression of GADD153 at the transcription level, the ability of ATF4 to transactivate the GADD153 gene, that both Gadd153 and ATF4 enhance the transcription of the b-casein promoter in a STAT5a-sensitive manner, and that GADD153 is developmentally expressed in the mammary gland during lactation.
Results

Identification of GADD153 as an HRG-inducible gene product
To identify HRG-inducible novel genes in mammary epithelial cells, we reasoned that if HRG use HER2 to regulate the expression of such putative genes, then interfering HER2 functions by anti-HER2 blocking antibody (Herceptin, HCT) may also modulate these genes. This indirect approach is dierent from the direct inducible approach which primarily identify inducible genes that may not be always repressed by HCT. Hence, we screened MDA-MB231 human breast cancer cells for genes whose expression may be downmodulated by the HCT using the Atlas human cancer cDNA expression array (Clonetech).
32 P-(a)-dCTP labeled cDNA was synthesized from control and Herceptin-treated MDA-MB231 cells (as described in Materials and methods), and hybridized with the ®lters. Initial screening identi®ed 20 dierentially expressed genes between control and HCT-treated cultures.
However, subsequent evaluation by RT ± PCR analysis indicated that only GADD153 gene was repressed by HCT, and there was no change in the expression of the remaining 19 genes between control and HCT-treated cultures (data not shown). The ampli®ed GADD153 band was subcloned into PCRII Topo cloning vector (Invitrogen) and con®rmed by sequencing (Genebank accession number S40706). Finally, Northern blot analysis was used to con®rm the repression of GADD153 mRNA by HCT in MDA-MB231 breast cancer cells, which have normal levels of HERs but are known to constitutively secrete HRG (Peles et al., 1992) using a 310-bp GADD153 probe. Treatment of these cells with HCT reduced the baseline expression of GADD153 mRNA (Figure 1a ). In addition, Herceptin treatment of BT-474 breast cancer cells, which overexpress HER2, was also associated with a reduced expression of GADD153 mRNA (Figure 1a) . To show the regulation of GADD153 expression by HRG in mammary epithelial cells, we next examined the levels of GADD153 mRNA in MCF-7 cells treated with HRG. Northern blot analysis showed a signi®cant increase in the steady-state level of 1.1 kb mRNA for GADD153 at 8 and 24 h after the HRG treatment ( Figure 1b) . A sub-optimal dose of HRG (0.1 nM) was sucient to upregulate the expression of Gadd153 mRNA ( Figure 1b, lane 4) .
In mammary epithelial cells, HRG predominantly uses HER3/HER2 to execute its biological eects (Hynes and Stern, 1994) . Earlier studies have shown the eectiveness of HCT in inhibiting HRG-induced heterodimerization of HER3/HER2 receptor (Adam et al., 1998) and also impairing the expression of HRGregulated genes Talukder et al., 2001) . To determine the role of growth factor receptor activity in the regulation of GADD153, we asked whether anti receptor antibodies against HER1-4 could down-regulate the steady-state level of GADD153 in HRG-treated cells. As shown in Figure 1c , cotreatment of MCF-7 cells with HRG and HCT blocked the ability of HRG to stimulate the expression of GADD153 mRNA (lane 2 and 4). Cotreatment of MCF-7 cells with an anti-HER3 monoclonal antibody against HRG binding site (Vadlamudi et al., 1999) , but not with anti-EGFR monoclonal antibody C225 or with anti-HER4 antibody (Fitzpatrick et al., 1998) blocked the ability of HRG to stimulate the expression of GADD153 (Figure 1d ). These observations suggested that HRG might utilize HER3 and HER2 receptors to up-regulate the expression of GADD153 in MCF-7 cells. In addition, EGF-stimulation of MDA-MB468 cells with high EGFR was also accompanied by the up-regulation of GADD153 mRNA in a C225-sensitive manner (Figure 1e , compare lane 4 with lane 2). These ®ndings suggested that GADD153 is an HRG-and EGF-inducible gene and that speci®c antireceptor antibodies could block growth factor regulated expression of GADD153 in breast cancer cells.
Expression and HRG regulation of GADD153 in the mammary epithelial cells in vivo
To demonstrate the physiological relevance of GADD153 in mammary glands, we next examined the expression of GADD153 during mammary gland development. In situ hybridization analysis of mouse mammary gland showed GADD153 mRNA signal was much stronger in the lactating mammary gland than in the pregnant mammary gland (Figure 2a ). To further establish the role of GADD153 in mammary epithelial cells, we next sought to demonstrate GADD153 expression in mammary gland cells. RNA was isolated from tissues representing various stages of mammary gland development, and the expression of GADD153 mRNA was analysed by Northern hybridization. In Figure 2b there were two distinct peaks of GADD153 mRNA expression, one at pregnancy day 15 and another during lactation. These results suggested that lactating mammary epithelial cells express GADD153
and that the GADD153 expression in mammary glands was developmentally-regulated.
HRG regulation of GADD153 expression
The observed HRG-mediated increase in GADD153 mRNA have been due to increased synthesis of newly transcribed mRNA, enhanced stability of GADD153 mRNA, or both. To delineate this possibility, we examined the eect of actinomycin D, an inhibitor of transcription. Pretreatment of cells with actinomycin D abolished the HRG-mediated induction of GADD153 mRNA, suggesting the need for continuous RNA synthesis in the observed increased expression of GADD153 mRNA in HRG-treated cells (Figure 3 
Regulation of transcriptional activity from the GADD153 promoter by HRG and HER2
To determine whether HRG activates GADD153 promoter activity, we examined the eect of HRG on transcription from a chimeric reporter system containing the 5'-¯anking sequences from 7954 to +91 of the human GADD153 gene and the CAT reporter gene (Park et al., 1992) . MCF-7 cells were transiently transfected with the GADD153-CAT in the presence or absence of HRG plasmid. As illustrated in Figure 5a , cotransfection with HRG stimulated the CAT reporter up to 11-fold compared with that in untreated control cells. Because HRG has also been shown to induce the expression and transactivating function of another bZIP transcription factor, ATF-4 , we explored whether ATF4 can activate transcription from the GADD153 promoter in breast cancer cells. As shown in Figure 5 , cotransfection of human ATF4 expression vector resulted in signi®cant stimulation of GADD153 promoter activity. This ®nding was consistent with a previous observation showing ATF4-mediated upregulation of GADD153 promoter activity in HeLa cells (Wolfgang et al., 1997) . Because the level of GADD153 expression was modulated by HER2 function in breast cancer cells (Figures 1 and 2) , we hypothesized that HER2 activation may enhance GADD153 promoter activity. To examine this possibility, MCF-7 cells were cotransfected with GADD153-CAT with either activated HER2 (pointmutated, HER2-NT) or wild-type HER2 (HER2-wt). We found that HER2-NT but not HER2-wt stimulated the GADD153 transcription. In addition, overexpression of activated HER2 in B104-1-1 cells (NIH3T3 cells stably expressing HER2-NT; Xie et al., 1995) was also accompanied by a signi®cant upregulation of GADD153 mRNA levels (Figure 5b ). These observations suggested that both HER2 and ATF4 may in¯uence the expression of GADD153 in breast cancer cells.
Regulation of the C/EBP-ATF composite motif in the GADD153 promoter by HRG and HER2 To understand the mechanism by which HRG mediates its eect on the GADD153 promoter, we explored the role of the C/EBP-ATF composite site in the regulation of GADD153 promoter activity by HRG or activated HER2. The C/EBP-luciferase construct was generously provided by Nikki J Holbrook (Fawcett et al., 1999) that contains tandem repeats of C/EBP-ATF-binding site (CATTGCAT-CATC) just upstream of the basal GADD153 promoter (736 to +21) to drive expression of a luciferase reporter gene. As shown in Figure 6a , both HRG and activated HER2 (HER2-NT) but not wildtype HER2 (HER2-wt) or vector alone stimulated the level of the C/EBP-ATF-luciferase activity.
Because the C/EBP-ATF composite site has been shown to be activated by ATF4 (Fawcett et al., 1999) which is also an HRG-inducible bZIP transcription factor , we next examined the eect of ATF4 in the presence or absence of HRG on the status of the composite site in MCF-7 breast cancer cells. Interestingly, ATF4 had a biphasic eect on the level of C/EBP-ATF-luciferase activity (Figure 6b ). The C/EBP-ATF luciferase activity was gradually stimulated by the lower levels (0.1 to 0.5 mg of DNA/ well) of ATF4 (Figure 6b ). In contrast, higher levels of ATF4 (greater than 0.5 mg of DNA/well) were inhibitory; the observed inhibitory eect was ampli®ed by HRG treatment (Figure 6b ). Tunicamycin (50 mg/ml for 16 h), a known inducer of GADD153, was used as a positive control. As both ATF4 and activated HER2 (HER2-NT) were potent inducers of GADD153 promoter activity, cotransfection of MCF-7 cells using both of these constructs was accompanied by a potentiating eect over the levels achieved by ATF4 or activated HER2 (HER2-NT) alone (Figure 6c) .
Together, results presented in Figures 5 and 6 suggested that both HRG and HER2 may use the C/ EBP-ATF composite site to stimulate GADD153 transcriptional activity and that ATF4 may play a role in this regulatory event.
Upregulation of GADD153 expression by HRG and lactogenic hormones in normal mammary epithelial cells
Using the HC11 mouse mammary epithelial cell model system, we investigated whether HRG regulates the expression of GADD153 in normal mammary epithe- (Marte et al., 1995) . In our studies, HRG treatment of HC11 cells signi®cantly increased the level of GADD153 mRNA (Figure 7a ). Next we investigated whether the lactogenic hormones dexamethasone, insulin, prolactin can in¯uence the expression of GADD153 which induce dierentiation and secretion of milk proteins (Marte et al., 1995) . Treatment of HC11 cells with insulin or prolactin but not dexamethasone signi®cantly upregulated the expression of GADD153 mRNA (Figure 7a ). The observed dierential eects of lactogenic hormones on the expression of GADD153 were unique in the sense that in the past, the expression of another HRGinducible gene, Rab3A, was regulated by dexamethasone but not by insulin or prolactin . The results presented in Figure 7b demonstrated Figure 6 Modulation of luciferase activity by tandem C/EBP-ATF elements in the GADD153 promoter. (a) MCF-7 Cells were transiently transfected with a luciferase reporter driven by tandem C/EBP-ATF elements in the GADD153 promoter and with activated HER2 (HER2-NT) or wild-type HER2 (HER2-wt) constructs or a control pcDNA vector (0.5 mg each). Some cultures were treated with or with out HRG (1 nM) for the indicated times before assaying for luciferase activity. (b) MCF-7 cells were transiently transfected with a luciferase reporter driven by tandem C/EBP-ATF elements in the GADD153 and increasing doses of ATF4 for 16 h. Some cultures were treated with or without HRG (1 nM for 16 h) before assaying for luciferase activity. Quantitation of luciferase activity is shown as fold induction over the control culture. Tunicamycin (50 mg/ml for 16 h) was used as a positive control. (c) MCF-7 cells were transiently transfected with a luciferase reporter driven by tandem C/EBP-ATF elements in the GADD153 (0.5 mg) and ATF4 (0.5 mg) with or without activated HER2 (HER2-NT) or control pcDNA vector (0.5 mg each). Quantitation of luciferase activity is shown as fold induction over the control culture that insulin and prolactin but not dexamethasone stimulated the level of C/EBP-ATF-luciferase activity.
GADD153 regulates b-casein expression in STAT5a-sensitive manner
The results described above suggested that the observed regulation of GADD153 expression by physiologically relevant molecules such as HRG and lactogenic hormones may have a role in the biology of mammary epithelial cells. Because HRG and lactogenic hormones are known to promote the dierentiation of mammary epithelial cells via up-regulating the expression of b-casein through the transcription factor STAT5a (Marte et al., 1995; Kazansky et al., 1999) , and enhances GADD153 expression (this study), we hypothesized that GADD153 may modulate b-casein expression. Hence, we sought to determine the eect of GADD153 on b-casein promoter (72300 to +490 bp)-luciferase activity in HC-11 cells. b-casein promoter contains several`CCAAT',`C/EBP',`CREB' and STAT transcription factors binding sites (Genebank accession number, AF027807). As shown in Figure 8a , transfection of GADD153 but not a control pcDNA vector led to increased transcription of the reporter system driven by the b-casein promoter in a dosedependent manner. Because b-casein promoter is regulated by STAT5a (Kazansky et al., 1999) , we explored the role of STAT5a in GADD153-mediated regulation of b-casein promoter activity. The results presented in Figure 8b demonstrated that cotransfection of GADD153 with wild-type STAT5a (Ariyoshi et al., 2000) induced the b-casein-luciferase activity whereas cotransfection of GADD153 with dominantnegative STAT5a completely blocked the ability of GADD153 to stimulate the b-casein promoter activity in MCF-7 cells. These results suggested that GADD153 may regulate b-casein expression via STAT5a in mammary epithelial cells.
Discussion
GADD153, a member of the bZIP family of transcription factors, has been shown to regulate a variety of cellular functions, including oxidative stress, growth arrest, and dierentiation. Among the bZIP transcription factors, the GADD153 gene is unique in that it contains a novel C/EBP-ATF composite site that is a hybrid of the C/EBP site and a variant ATF site. Because both the C/EBP and ATF sites are also present in a variety of genes having roles in growth regulation, the GADD153 gene may potentially be regulated by diverse nuclear factors. Furthermore, because it is a ZIP-containing factor, GADD153 protein can interact with the members of C/EBP and ATF and thus sequester these factors from binding to their DNA motif. Accordingly, it is generally believed that GADD153 may negatively regulate C/EBP-or ATF3-mediated gene activation (Fawcett et al., 1996; Chen et al., 1996) . However, GADD153 also has been shown to activate transcription from a novel DNAbinding motif, i.e. the calmodulin-responsive element (Ubeda et al., 1996) . These observations suggest that GADD153 may in¯uence the transcriptional outcome in both a negative and a positive manner. However, no information is available about GADD153 expression and its potential modulation by growth factors in mammary epithelial cells.
HRG has been shown to modulate the growth, dierentiation, and motility of breast cancer cells. The multifunctional nature of HRG is thought to be dependent on induced changes in expression, modi®ca-tion, or both of speci®c cellular gene products. Because Figure 7 Regulation of GADD153 expression in normal mammary epithelial cells. (a) HC11 cells grown and maintained at con¯uency in dierentiation medium (8% fetal calf serum, 5 mg/ml bovine prolactin (P), 5 mg/ml insulin, 1 mM dexamethasone 10 ng/ml murine EGF) for 6 days. Than cells are serum starved for 48 h and treated with D, I, P, and 0.1, 0.5, 1.0 nM HRG for 16 h. Total RNA was isolated, and the level of GADD153 mRNA was detected by Northern hybridization. (b) HC11 Cells were transiently transfected with a luciferase reporter driven by tandem C/EBP-ATF elements in the GADD153 promoter (0.5 mg/ml). After 24 h of transfection, cells were treated for another 24 h with dexamethasone (D), insulin (I), and prolactin (P) before luciferase assay. The results are representative of three experiments we identi®ed GADD153 as one of the HRG-inducible genes and GADD153 interacts with a wide spectrum of bZIP transcriptional factors that potentially regulate cellular functions, we explored the possible involvement of GADD153 in the action of HRG using mammary epithelial cells as a model system. The results presented here indicate that treatment of mammary epithelial cells with HRG induced signi®-cantly higher levels of GADD153 expression.
Our conclusion that HRG is a very potent inducer of GADD153 expression is supported by the following lines of evidence: (1) HRG stimulated the expression of Gadd153 mRNA as early as 8 h after treatment; (2) elevated expression of GADD153 mRNA was sensitive to the transcriptional inhibitor; (3) HRG-induced upregulation of GADD153 mRNA did not require de novo protein synthesis; (4) HRG stimulated the expression of newly synthesized 35 S-labeled GADD153 protein; (5) HRG enhanced transcription from the GADD153 promoter; and (6) HRG upregulated transcription from the C/EBP-ATF composite site in the GADD153 promoter. These ®ndings established that GADD153 is a bona-®de HRG-inducible gene product. Furthermore, the induction of GADD153 expression by HRG was not a phenomenon restricted to MCF-7 cells, as HRG also induced expression of GADD153 mRNA in normal mammary epithelial cells. The expression and induction of GADD153 protein by HRG opens a whole new area of investigation regarding the role of bZIP transcription factors in HRG activity.
Another notable ®nding of this study was the potential role of HRG-initiated signals in the transcriptional activation of genes containing ATF sites, such as GADD153 (this study), and those containing CRE sites, such as ATF4 . The evidence showing that cotransfection of ATF4 has the capacity to activate Gadd153 promoter-driven transcription is of special interest as it strongly suggests that earlier reported HRGinduced ATF4 expression may contribute to modulation of the expression of GADD153 containing ATF binding sites directly, indirectly, or both by in¯uen-cing the physical interactions with ATF4. These observations, together with the fact that the GADD153 promoter itself contains ATF sites (Fawcett et al., 1999) and ATF4 is another HRGinducible gene product, raise the possibility of a autoregulatory role for increased ATF4 DNA-binding activity in the induction of GADD153 expression in HRG-stimulated cells. Because HRG is a paracrine growth factor in mammary glands, the observed HRG-mediated stimulation of GADD153 expression may potentially use the ATF4 transcription factor to regulate Gadd153 expression in the biology of mammary epithelial cells. Earlier studies showed that HRG induces dierentiation in mammary epithelial cells (Marte et al., 1995) , and dierentiation is an essential function of mammary gland cells during lactation. Our data showed that HRG induces GADD153 expression which in turn upregulates the expression of b-casein in a STAT5a-sensitive manner. These ®ndings suggest that GADD153 may function in the HRG regulation of mammary epithelial cell dierentiation. This notion is further supported by the ®nding that GADD153 expression was induced by the lactogenic hormones insulin and progesterone but not dexamethasone. Because another HRG-regulated gene, Rab3A, has been shown to be upregulated by dexamethasone , these results raise the possibility that distinct pathways lead to GADD153 regulation in mammary epithelial cells. Additional support for a physiological role for GADD153 in the mammary gland is provided by the ®nding that a murine mammary gland model showed elevated expression of GADD153 in the early lactating stages.
Data from the literature suggest that in addition to transactivation, GADD153 may also act as a transcriptional repressor, presumably due to the sequestration of factors and cofactors from the proximity of the target promoter (Marte et al., 1995; Jones et al., 1996) . In view of these ®ndings, it seems reasonable to speculate that HRG may also use inducible modi®ca-tion of GADD153 to potentially repress the expression of unidenti®ed cellular genes that negatively regulate the dierentiation or invasiveness of mammary epithelial cells.
Although we demonstrated stimulation of b-casein as an example of transcriptional activation of a cellular gene by GADD153 in HRG-treated cells, our ®ndings may have a general implication for regulation of cellular genes using a C/EBP or ATF site or motif by HRGinducible signals. Another emerging concept from our present investigation is the possibility that HRG regulation of GADD153 may provide an explanation for the multiple cellular functions of HRG because binding sites for C/EBP and ATF factor are present in several growth-regulating cellular promoters and because GADD153 interacting factors, particularly C/ EBP, are widely believed to be involved in integrating regulatory signals from distinct pathways (Janknecht and Hunter, 1996) . Together, these events may lead to dierential regulation of the genes that may participate in the mediation of HRG in breast cancer cells. In summary, the results of our study demonstrate the regulation of GADD153 expression by physiologically relevant molecules in mammary epithelial cells and GADD153 may serve as a downstream eector of HRG in the dierentiation of mammary epithelial cells.
Materials and methods
Cell cultures and reagents
Human breast cancer cells MCF-7, BT-474, MDA-MB231 and MDA-MB435 , and vulvar carcinoma A-431 cells were maintained in Dulbecco's modi®ed Eagle's medium-F12 (1 : 1) supplemented with 10% fetal calf serum. HC11 mouse epithelial cells (generously provided by Daniel Madina, Baylor College of Medicine, Houston, TX, USA) were maintained in RPMI-1640 medium supplemented with 8% fetal calf serum, 10 ng/ ml EGF and 5 mg/ml insulin. Antibody against Gadd153 was purchased from the Santa Cruz (Santa Cruz, CA, USA). Lactogenic hormone treatment and preparation of competent HC11 cells was performed according to Marte et al., 1995. Cell labeling, cell extracts, and immunoprecipitation An equal number of cells were metabolically labeled for 4 ± 8 h with 100 mCi/ml [ 35 S]methionine in methionine-free medium containing 2% dialyzed fetal bovine serum in the absence or presence of indicated treatments. For preparation of cell extracts, cells were washed three times with phosphate buered saline and lysed in RIPA buer supplemented with 100 mM NaF, 200 mM NaVO 5 , 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml apotinin for 15 min on ice. The lysates were centrifuged in an Eppendorf centrifuge at 48C for 30 min. Cell lysates containing equal tri-chloroacetic acid perceptible counts were immunoprecipitated with the desired antibody, resolved on SDS-PAGE, and analysed .
Atlas cDNA array screening, RT ± PCR, and Southern hybridization
To better understand the mechanism of Herceptin (HCT) action in breast cancer cells, we screened the nature of HCTrepressible genes in MDA-MB231 cells using the Atlas human cancer cDNA expression Array (Clonetech). Total RNA was isolated from control and HCT (20 ng/ml for 4 h) treated cells, cDNA were synthesized by Reverse Trasncriptase in the presence of 32 P-(a)-dCTP, and hybridized with gene-array ®lters. This primary screening resulted in the identi®cation of 20 HCT-modulated genes. To con®rm the results of the initial screening, primers against all 20 genes were purchased from the Clonetech and expression of genes was analyzed by RT ± PCR using control and HCT-treated total RNA. The forward primer for GADD153 was 5'-GAAACGGAAACAGAGTGGTCATTCCCC-3' and the reverse primer was 5'-GTGGGATTGAGGGTCACAT-CATTGGCA-3'. The RT ± PCR for GADD153 and other genes were done according to the manufacturer's instruction using Access RT ± PCR systems (Promega). For Southern hybridization, total cytoplasmic RNA was isolated from dierent stages of mouse tissue using the Trizol Reagent (GIBCO ± BRL) and 500 ng of RNA analysed by RT ± PCR. RT ± PCR products were run onto 1-% agarose gel, transferred to a blot and probed with a 510 bp cDNA of GADD153.
Northern hybridization
Total cytoplasmic RNA was isolated using the Trizol Reagent (GIBCO ± BRL) and 20 mg of RNA analysed by Northern hybridization using a 510 bp cDNA of human GADD153. rRNA (28S and 18S) was used to assess the integrity of the RNA and for RNA-loading and transfer control, the blots were routinely reprobed with human GAPDH cDNA. In some experiments, cells were treated with 50 mg/ml cyclohexamide (a translational inhibitor) or 10 mg/ml actinomycin D (a transcriptional inhibitor) in the presence or absence of HRG (1 nM) treatment. HC11 cells grown and maintained at con¯uency in dierentiation medium (8% fetal calf serum, 5 mg/ml bovine prolactin (P), 5 mg/ml insulin, 1 mM dexamethasone 10 ng/ml murine EGF) for 6 days. Then cells are serum-starved for 48 h and treated with 0.1, 0.5, 1.0 nM HRG for 16 h and with lactogenic hormones, 5 mg/ml insulin, 5 mg/ml prolactin and 1 mM dexamethazone in the absence of serum.
Transfection and promoter assays
Cells were splitted in 100-mm tissue-culture dishes for CAT assay or 6-well plates for luciferase assay 24 h before transfection. Subcon¯uent cells were transiently transfected with GADD153 CAT (containing the promoter region of the human GADD153 gene from 7954 to +91 relative to the transcription start site) (Park et al., 1992) , or with C/EBPluciferase (it contains the tandem repeats of the C/EBP-ATF binding site (CATTGCATCATC) linked to the upstream of the GADD153 minimal promoter 736 to +21) (Fawcett et al., 1999) and with other constructs as needed or control pCMV vector using Lipofectamine method (Gibco ± BRL). After 5 h of transfection, medium was changed to DMEM containing 10% serum. After 24 h, cultures were shifted to 0% serum (for growth factor treatment) for 12 h before harvesting. CAT or luciferase activity was measured 48 h after transfection using a CAT or luciferase assay kit (Promaga) (Talukder et al., 2001) . When indicated, cells were treated with HRG (1 nM) or lactogenic hormones. Each experiment was repeated three to six times and transfection eciency varied between 30 ± 50%.
In-situ hybridization
For in-situ hybridization, mouse mammary gland tissues or 12 day old embryos were cut out and ®xed with 10% neutral buered formaldehyde and processed routinely to paran sections as described (Mazumdar et al., 2001) In situ hybridization was done by using the digoxigenin (Roche) labeled riboprobe. A 309 bp of mouse Gadd153 cDNA corresponding to the human Gadd153 mRNA (480 ± 789 region) was ampli®ed by RT ± PCR, subcloned into TOPO II vector (Promega) and used for riboprobe synthesis under the control of T7 promoter. RNA probes were labeled with digoxigenin and hybridized for 16 ± 20 h in buer containing 1 mg/ml riboprobes, 50% formamide, 300 mM NaCl, 10 mM Tris (pH 7.4), 10 mM NaH 2 PO 4 (pH 6.8), 5 mM EDTA (pH 8.0), 0.2% Ficoll 400, 0.2% polyvinyl pyrolidone, 10% dextran sulfate, 200 mg/ml yeast total RNA, and 50 mM dithiothreitol. Alkaline phosphatase labeled sheep antidigoxigenin antibody was applied and signals were visualized by NBT-BCIP. Hybridization with sense-probe was used as background control.
Abbreviations HRG, heregulin-b1; HER, Human EGF Receptor; HCT, anti-HER2 antibody herceptin; RT ± PCR, reverse transcriptase polymerase chain reaction; ATF, activating transcription factor; bZIP, basic leucine zipper; CRE, cAMP response element; CREB, CRE-binding protein; CBP, CREB-binding protein; GADD, growth arrest and DNA damage-inducible protein; Dex, dexamethasone; C/ EBP, CCAAT -enhancer -binding protein; CHOP, C/EBP homologous protein; NBT, nitro blue tetrazolium; BCIP, 5-bromo-4-chloro-3-indolyl phosphate.
